Palo Alto, California-based Kodiak Sciences Inc, a biopharmaceutical company focused on treating chronic retinal diseases, has priced its IPO of 9 million shares at between $13 and $15 per share. Kodiak will list the stock on the NASDAQ under the ticker symbol “KOD.” Morgan Stanley and BofA Merrill Lynch are the lead underwriters. Kodiak is backed by ArrowMark Partners and Perceptive Advisors, according to Crunchbase.
Palo Alto, CA, September 24, 2018 – Kodiak Sciences Inc. (“Kodiak”) today announced that it has launched an initial public offering of 9,000,000 shares of its common stock at an anticipated initial offering price between $13.00 and $15.00 per share pursuant to a registration statement on Form S-1 (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (the “SEC”). In addition, Kodiak intends to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of Kodiak’s common stock at the initial public offering price, less underwriting discounts and commissions. Kodiak has applied to list the shares on the Nasdaq Global Market under the ticker symbol “KOD.”
Morgan Stanley and BofA Merrill Lynch are acting as joint book-running managers for the proposed offering. Barclays is also acting as a book-running manager for the offering. Chardan will act as lead manager.
The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or email firstname.lastname@example.org; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or email email@example.com.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Kodiak Sciences Inc.
Kodiak Sciences Inc. is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases.